Collaborations & Alliances

Triphase, Celgene in Strategic ADC Alliance

Celgene has an option to acquire all Triphase assets relating to TRPH-222

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Triphase Accelerator Corp. has entered a strategic collaboration with Celgene Corp. under which Celgene has an option to acquire all Triphase assets relating to TRPH-222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma. Triphase received an upfront payment and will control development and retains all commercial rights to TRPH-222 (CD22-4AP). If Celgene exercises its option, it will become responsible for development and commercialization, and Triphase will be eligible to re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters